Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice

Nikolov, Igor G; Joki, Nobuhiko; Galmiche, Antoine; Nguyen-Khoa, Thao; Guerrera, Ida Chiara; Guillonneau, François; Ivanovski, Ognen; Phan, Olivier; Maizel, Julien; Marçon, Frédéric; Benchitrit, Joyce; Lucas, Anthony; Edelman, Aleksander; Lacour, Bernard; Drüeke, Tilman B; Massy, Ziad A

doi:10.1016/j.atherosclerosis.2013.02.041

Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice

Journal

Atherosclerosis

Date Issued

2013-07

Author(s)

Joki, Nobuhiko

Galmiche, Antoine

Nguyen-Khoa, Thao

Guerrera, Ida Chiara

Guillonneau, François

Phan, Olivier

Maizel, Julien

Marçon, Frédéric

Benchitrit, Joyce

Lucas, Anthony

Edelman, Aleksander

Lacour, Bernard

Drüeke, Tilman B

Massy, Ziad A

DOI

10.1016/j.atherosclerosis.2013.02.041

Abstract

Atherosclerosis and vascular calcification are major contributors to cardiovascular morbidity and mortality among chronic kidney disease patients. The mevalonate pathway may play a role in this vascular pathology. Farnesyltransferase inhibitors such as R115777 block one branch of mevalonate pathway. We studied the effects of farnesyltransferase inhibitor R115777 on vascular disease in apolipoprotein E deficient mice with chronic renal failure and on mineral deposition in vitro.